PRESS RELEASE – UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute

MRI confirms complete healing of hamstring eight weeks after Dr. Wade McKenna administered guided injections of bone marrow aspirate concentrate (BMAC) harvested with BioMAC (patent pending) bone marrow aspiration cannula and AlphGEMS amniotic tissue product at the Riordan-McKenna Institute.

DALLAS-FORT WORTH, TEXAS (PRWEB) SEPTEMBER 03, 2015

Zack Bornstein with Dr. McKenna and Physicians Assistant, Troy Chandler

Zack Bornstein with Dr. McKenna and Physicians Assistant, Troy Chandler

UCLA wide receiver and Canadian decathlon standout, Zack Bornstein suffered a hamstring tear 18 months ago. Conventional treatment and therapy were not working so Zack decided to undergo stem cell therapy at Riordan-McKenna Institute in late June 2015. Dr. McKenna treated Zack with precisely guided injections of bone marrow aspirate concentrate (BMAC) harvested with the BioMAC (patent pending) bone marrow aspiration cannula and *AlphGEMS amniotic tissue product.

Complete healing was confirmed by MRI 8 weeks after treatment:

1) No evidence for hamstring strain or denervation and no evidence for tendon tear.
2) No evidence for focal atrophy or hematoma.
3) No osseous abnormalities seen.

After receiving the MRI results, Zack’s father Dean said, “I am not a doctor but looks like you and your procedure has performed a medical miracle! …Thanks for all of your efforts.”

Zack is currently a red shirt freshman at UCLA. He played football at Oaks Christian High School from 2011-’14 and lettered 3 years in football and all 4 years in track. In 2013, Zack was named to the All-Marmonte 2nd team. He played in the FBU Youth All-American game in 2010. In track, he is considered to be one of the top decathletes in the country. Zack competed at the 2013 Pan American Junior Championships in Medellin, Columbia, finishing in 5th place with 7,097 points. In July of 2013, he became the Canadian Junior National Champion (6,918 pts). Zack won the silver medal at the 2013 Arcadia Invitational Decathlon, scoring 6,967 points to set a new California state record for juniors (2nd highest score in California state history). Zack is a 12-time National Champion, 44-time All-American and a member of three National Championship cross country teams.

About Riordan-McKenna Institute (RMI)

RMI specializes in non-surgical treatment of acute and chronic orthopedic conditions using *AlphaGEMS flowable amniotic tissue allograft and bone marrow aspirate concentrate (BMAC) that is harvested using the patented BioMAC bone marrow aspiration cannula. Common conditions treated include meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis. RMI also uses AlphaPATCH amniotic membranes as part of a complete wound care treatment regimen.

RMI also augments orthopedic surgeries with BMAC and AlphaGEMS to promote better post-surgical outcomes.
BMAC contains a patient’s own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. AlphaGEMS is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.

*AlphaGEMS and AlphaPATCH products are produced by Amniotic Therapies Inc. from donated amniotic tissue after normal healthy births. For more information about AlphaGEMS, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/

http://www.rmiclinic.com

801 E. Southlake Blvd.
Southlake, Texas
76092

Tel: (817) 776-8155
Toll Free: (877) 899-7836
Fax: (817) 776-8154

About Amniotic Therapies

Based in Dallas, Texas, Amniotic Therapies specializes in the processing and distribution of human amniotic tissue products for the biologic and regenerative medicine segments of the healthcare market. Amniotic Therapies’ mission is to provide superior human amniotic tissue products that naturally enhance the body’s healing ability, providing patients with improved healing.
Amniotic Therapies is registered with the U.S. Food and Drug Administration (FDA) and is in the process of receiving accreditation from the American Association of Tissue Banks.

http://www.amniotictherapies.com

11496 Luna Rd. Suite 800
Dallas, Texas
75235

Tel: (972) 465-0496

Case report of non-healing surgical wound treated with dehydrated human amniotic membrane

AlphaPATCH Amniotic Membrane PictureDr. Riordan and Dr. Wade McKenna recently published this case study demonstrating how amniotic tissue products promote wound healing. You can view the original article on the Journal of Translational Medicine website: Case report of non-healing surgical wound treated with dehydrated human amniotic membrane.

Authors
Neil H Riordan, Ben A George, Troy B Chandler, Randall W McKenna

Abstract

INTRODUCTION
Non-healing wounds can pose a medical challenge as in the case of vasculopathic venostasis resulting in a surgical ulcer. When traditional approaches to wound care fail, an amniotic patch (a dehydrated tissue allograft derived from human amnion) can function as a biologic scaffold to facilitate and enhance tissue regeneration and rehabilitation.

BACKGROUND
Amniotic AlphaPatches contain concentrated molecules of PGE2, WNT4, and GDF-11 which have angiogenic, trophic, and anti-inflammatory effects on tissues that may be useful in enhancing wound healing.

AIM-CASE REPORT
We present a case of a severe non-healing surgical wound in a 78-year-old male 17 days post right total knee arthroplasty. The full-thickness wound exhibited a mobile flap, measured 4 cm long × 3 cm wide, and showed undermining down to patellar tissue. We treated the wound conservatively for 6 weeks with no evidence of wound healing. Upon failure of the conservative treatment, two amniotic AlphaPatch (Amniotic Therapies, Dallas, TX, USA) were applied to the wound, and the wound healed completely in 10 weeks.

METHODS
In the OR, the wound was irrigated with three liters of double antibiotic solution under pulse lavage. Two dry amniotic AlphaPatch (4 cm × 4 cm) were placed over the wound with Acticoat applied on top.

RESULTS
At the two-week follow-up visit (following the incision and drainage of the wound dehiscence and application of the amniotic AlphaPatch), a central scab had formed centrally in the wound dehiscence area. At the four-week follow-up visit, the wound dehiscence area had completely scabbed over with no open areas left. At the eight-week follow-up visit, the scab had just fallen off, and the wound was healing well with immature skin representing the size of a penny. At the ten-week follow-up visit, the wound was completely healed.

DISCUSSION/CONCLUSION
Sterile, dehydrated amniotic tissue AlphaPatches (containing trophic factors known to enhance wound healing) have proven effective in completely healing an otherwise non-healing wound in a 78-year-old male who failed six weeks of conservative wound care treatment.

Picture of wound before treatment with AlphaPATCH amniotic membrane

Picture of wound 2 weeks after treatment with AlphaPATCH amniotic membrane

Picture of wound 4 weeks after treatment with AlphaPATCH amniotic membrane

Picture of wound 8 weeks after treatment with AlphaPATCH amniotic membrane

Picture of wound 8 weeks after treatment with AlphaPATCH amniotic membrane

PBS to Feature Stem Cell Therapy at Stem Cell Institute and Medistem Labs Panama in TV Special

PBS is in Panama this week filming Stem Cell Institute’s clinic, staff and patients. Yesterday, they toured Medistem Labs Panama. Here are a few pictures taken by Dr. Riordan at the lab. Watch for this special to air on PBS this fall.

PBS at Medistem Labs in Panama 4

PBS at Medistem Labs in Panama 3

PBS at Medistem Labs in Panama 2

PBS at Medistem Labs in Panama 1

Copa Airlines Magazine Features Stem Cell Therapy at the Stem Cell Institute in Panama

Stem Cell Therapy for Multiple Sclerosis: Ron McGill

Ron McGill suffers from relapsing-remitting multiple sclerosis. He was started experiencing symptoms in 2009 but was not diagnosed with MS until January of 2013. He received several infusion and injections of human umbilical cord-tissue derived stem cells at the Stem Cell Institute in late October and Early November 2013.

In this video, Ron shares his story of discovery and recovery at a Stem Cell Institute seminar in San Antonio in October 2014.

For more information on MS therapy at the Stem Cell Institute in Panama, please visit: https://www.cellmedicine.com/stem-cell-therapy-for-multiple-sclerosis-3/

Good afternoon.

I was diagnosed with relapsing-remitting MS in January of 2013. My symptoms started with tingling and numbness in my hands and feet migraine headaches in April, 2009. Visits to the doctors concluded that job stress-related migraines were all it was.

My high tolerance for pain accepted the results and I went on with life. This was an extremely poor decision on my part. My symptoms remained constant but non-progressing until November of 2011. In attempting to kick a soccer ball, I lost my balance and I fell. I wrote it off as being out of shape and clumsy. A fall on a treadmill and down a stairwell in early 2012 was my final wakeup call. It solidified that there was more wrong with me than normal.

My quest to find out what was causing my issues and how to resolve them was started.

Starting from behind and (inaudible) to catch up, I did several things. I made immediate dietary changes. Sodas, fast food, canned food, alcohol – eliminated. Red meat, dairy, bread, pasta – reduced drastically. Chicken, fish, fresh fruits, vegetables – doubled. I went on a weight loss and body detox regimen. I replaced impact aerobic exercises I could no longer do with swimming.

I made the most of my insurance. I literally became a human pin cushion. Everybody was sticking me. I looked outside traditional medicine: acupuncturist, building my immune system and pure vitamin regimens. While I made great strides in changing my life, I was testing healthier, a progression of worse symptoms continued to happen. Severe leg and back aches, leg stingers, twitching, lost grip and more loss of balance.

It was determined that MS was my cause. My instability had me falling one to two times a month. I reached my lowest point waking up immobile from the waist down on a Wednesday morning in February of 2013.

With my motor skills seemingly erased from my memory, a deep cloud of panic overtook me. My confidence went out the window. I had to dig down extremely deep. I was able to regain mobility later that evening. I progressed to a penguin walk and very limited speed and distance over the next 6 months with the help of a walking stick and physical therapy.
Hours of online research for possible relief led to stem cell therapy.

After many months of research, doctor consultations, numerous conversations with people who had had stem cell therapy, heard about it, had relatives who had experienced it, I sent the email to the Stem Cell Institute.

After being accepted, I still had more conversations with Dr. Barnett and Cindy, asking more and more questions. They were extremely patient to everything I had.

The care provided for me upon my arrival and during my stay and departure in Panama was extremely good. The facility was simple, clean, efficient with a very helpful and friendly staff. The procedure was well-explained to me and carefully administered.

I was able to see results on my way back (on) November 3rd. I was able to walk farther and feel better. I was able to my walking stick in the back of my car for good two weeks later. Knock on wood, I haven’t fallen since October 23rd of 2013. My stamina, walking speed and stability have continued to increase. I do have momentary balance loss and heat can still wipe me out. My MS is still with me.

Do I feel (that) Panama was the right choice? For me, absolutely. I feel the infusion of healthy cells gave my body a huge boost to recover the majority of lost motor skills I had experienced. It also helped amplify the lifestyle changes I was already making to give me a faster and more positive result.

These successes have given me a more positive mental state that have allowed me to heal more and more.

What advice could I give you about stem cells? Research, research, research. There isn’t a price you can put on due diligence when it comes to your health. Make lifestyle changes at the cellular level in your body and amplify it with stem cell therapy.

In closing, I’d like to thank my wife for undying support and hours of research. I’d like to thank Dr. Riordan, (and) Stem Cell Institute for being at the cutting edge of healing diseases and I’d like to thank you all for allowing me to share with you today.

The Lip TV News: Neil Riordan, PhD on Exploring New Stem Cell Treatments for MS, Arthritis, Autism and More

Stem cell treatment and research towards curing illness–from multiple sclerosis to spinal injury–is detailed by Dr. Neil Riordan. The American medical industry, obstructions to research in the states, misconceptions about stem cells, and the details about the treatment process are explained–and we look at video of patient recovery and speculate at what the future could spell for stem cell treatment and research in this Lip News interview, hosted by Elliot Hill.

GUEST BIO:
Dr. Neil Riordan is the founder and Chairman of Medistem Panama, a leading stem cell laboratory and research facility – located in Panama City. His institute is at the forefront of research of the effects of adult stem cells on the course of several chronic diseases. Dr. Riordan has more than 60 scientific articles in international peer-reviewed journals. In the stem cell arena, he and his colleagues have published more than 20 articles on Multiple Sclerosis, Spinal Cord Injury, Heart Failure, Rheumatoid Arthritis.

Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase

Chicago, Illinois (PRWEB) October 30, 2014

On October 26th at the Mid American Regenerative and Cellular Medicine Showcase in Chicago, leading applied stem cell research scientist Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna presented talks on New Techniques for Enhancing Stem Cell Therapy Effectiveness and Orthopedic Surgical Applications For Stem Cells.

Dr. Riordan focused on historical medical uses of amniotic membrane and the properties of AlphaGEMS that include: wound healing; inflammation and pain reduction; fibrosis risk reduction; growth factor source; adhesion reduction; regeneration support and stem cell enhancement, specifically regarding the mesenchymal stem cells contained within BMAC.

Dr. McKenna discussed the latest applications of BMAC stem cells in orthopedic surgeries like anterior cruciate ligament (ACL) reconstruction and how BMAC injections can virtually eliminate infection risk, reduce complications, increase graft strength, reduce post-surgical inflammation and significantly reduce recovery time. Dr. McKenna also talked about how bone marrow can now be safely and relatively painlessly harvested using his patented BioMAC catheter under local, not general anesthesia.

Dr. Riordan and Dr. McKenna are co-founders of the Riordan-McKenna Institute (RMI), which will be opening soon in Southlake, Texas. RMI will specialize in regenerative orthopedics including non-surgical stem cell therapy and stem cell-enhanced surgery using bone marrow aspirate concentrate (BMAC) and AlphaGEMS amniotic tissue product.

Other noteworthy speakers in attendance included: Paolo Macchiarini, MD-PhD, Arnold Caplan, PhD and Mark Holterman, MD-PhD. Dr. Macchiarini and Dr. Holterman are well known for their work on the first stem cell trachea transplant. Dr. Caplan discovered the mesenchymal stem cell and is commonly referred to as the father of the mesenchymal stem cell.

About Neil Riordan PhD

Dr. Riordan is the co-founder of the Riordan-McKenna Institute (RMI), which will be opening soon in Southlake, Texas. RMI will specialize in regenerative orthopedics including non-surgical stem cell therapy and stem cell-enhanced surgery using bone marrow aspirate concentrate (BMAC) and AlphaGEMS amniotic tissue product.

Dr. Riordan is founder and chief scientific officer of Amniotic Therapies Inc. (ATI). ATI specializes in amniotic tissue research and development. Its current product line includes AlphaGEMS and AlphaPATCH amniotic tissue-based products.

Dr. Riordan is the founder and chairman of Medistem Panama, Inc., (MPI) a leading stem cell laboratory and research facility located in the Technology Park at the prestigious City of Knowledge in Panama City, Panama. Founded in 2007, MPI stands at the forefront of applied research on adult stem cells for several chronic diseases. MPI’s stem cell laboratory is ISO 9001 certified and fully licensed by the Panamanian Ministry of Health. Dr. Riordan is the founder of Stem Cell Institute (SCI) in Panama City, Panama (est. 2007).

Under the umbrella of MPI subsidiary Translational Biosciences, MPI and SCI are currently conducting five IRB-approved clinical trials in Panama for multiple sclerosis, rheumatoid arthritis and osteoarthritis using human umbilical cord-derived mesenchymal stem cells, mesenchymal trophic factors and stromal vascular fraction. Additional trials for spinal cord injury, autism and cerebral palsy are slated to commence in 2014 upon IRB approval.

Dr. Riordan is an accomplished inventor; listed on more the 25 patent families, including 11 issued patents. He is credited with a number of novel discoveries in the field of cancer research since the mid-1990s when he collaborated with his father Dr. Hugh Riordan on the effects of high-dose intravenous vitamin C on cancer cells and the tumor microenvironment. This pioneering study on vitamin Cs preferential toxicity to cancer cells notably led to a 1997 patent grant for the treatment of cancer with vitamin C. In 2010, Dr. Riordan received another patent for a new cellular cancer vaccine.

Dr. Riordan is also the founder of Aidan Products, which provides health care professionals with quality nutraceuticals including Stem-Kine, the only nutritional supplement that is clinically proven to increase the amount of circulating stem cells in the body for an extended period of time. Stem-Kine is currently sold in 35 countries.

Dr. Riordan earned his Bachelor of Science at Wichita State University and graduated magna cum laude. He received his Masters degree at the University of Nebraska Medical Center. Dr. Riordan completed his education by earning a Ph.D. in Health Sciences at Medical University of the Americas.

About Dr. Wade McKenna

Dr. Wade McKenna is cofounder of the Riordan-McKenna Institute. He is a leading advocate of Autologous Stem Cell Therapy and Regenerative Medicine focusing on advancing the clinical benefits in orthopedics.

Board certified in orthopedic surgery, Dr. McKenna is the chief medical officer and co-founder of Biologic Therapies, a product development and research company dedicated to the advancement of autologous adult stem cell therapy. His achievements include the recent development of the BioMac bone marrow aspiration catheter, treating world-class athletes, and developing numerous surgical and non-surgical stem cell application protocols.

After receiving his undergraduate degree and earning his medical degree at Oklahoma State University, Dr. McKenna completed his orthopedic residency at the Dallas/Ft Worth Medical Center and his trauma fellowship at Tampa General Hospital. With over 20 years in private practice, Dr. McKenna has successfully built McKenna Orthopedics in Trophy Club, Texas and North Central Texas Orthopedics & Sports Medicine in Decatur, Texas.

Dr. McKenna has a proven track record of producing positive clinical outcomes augmented by concentrated, autologous bone marrow aspirate. Dr. McKenna has applied this stem cell-enriched product to thousands of surgical and non-surgical patients. Successful applications include long bone non-unions; avascular necrosis of the femoral head; severe clavicle non-unions; cartilage regeneration; chondrogenesis and soft tissue repair of the shoulder; chronic tendonopathy; tendon ruptures; numerous applications to common, often difficult foot and ankle injuries; and wrists fractures.

Riordan-McKenna Institute
www.rmiclinic.com
801 E. Southlake Blvd.
Southlake, Texas
76092

Tel: (817) 776-8155
Toll Free: (877) 899-7836
Fax: (817) 776-8154

A Review of Therapeutic Effects of Mesenchymal Stem Cell Secretions and Induction of Secretory Modification by Different Culture Methods

Stem Cells Used to Successfully Treat Chronic Achilles Tendon Injury

Ocala, FL, October 06, 2014 –(PR.com)-Biologic Therapies, Inc. (BTI), a company that specializes in the design and development of medical devices and procedures for the regenerative medicine market, announced today that its products have been used to successfully treat a chronically injured Achilles tendon with stem cell therapy.

A case report, titled ‘Minimally Invasive Autologous Bone Marrow Concentrate Stem Cells in the Treatment of the Chronically Injured Achilles Tendon: A Case Report’, was authored by Biologic Therapies’ Chief Medical Director, Dr. R. Wade McKenna, and Chief Scientific Officer, Dr. Neil H. Riordan, founders of the Riordan-McKenna Institute in Southlake, Texas, USA (www.rmiclinic.com).

The case involved a 56-year-old female patient complaining of a painful “knot” in her left Achilles tendon. The pain limited her ability to perform daily activities such as shopping or being up on her feet for longer than 30 minutes. She had been an active tennis player and recreational athlete, but had not been able to play tennis or jog for ten years. She reported significant pain when relaxing and great pain when walking. The patient had been to multiple physicians and had followed ten years of standard treatment with stretches and anti-inflammatories. She refused multiple offers of invasive surgery that could not promise a return to tennis.

On physical examination by Dr. R. Wade McKenna, the patient had a large, palpable knot in the Achilles tendon, very noticeable and acutely tender. An MRI scan showed severe hypertrophic changes with marked tendinopathy.

The patient received a point-of-care stem cell therapy treatment in Dr. McKenna’s office as an outpatient procedure using Biologic Therapies products. The physician drew bone marrow from her tibia (shin) bone, processed the marrow in a centrifuge to concentrate the stem cells and growth factors, then injected the stem cells and growth factors into and around her injured Achilles tendon. Prior to the injection of the concentrated stem cells and growth factors, an injection of local anesthesia was given to prevent pain. The patient reported little to no pain during or after the procedure.

After six weeks the patient reported no pain at rest and minimal pain while walking. After eight weeks, there was even less pain while walking. The knot was less than 50% of the pre-treatment size and was relatively non-tender to touch. She was back to playing tennis without significant pain or difficulty. After ten weeks the patient was doing much better. An MRI scan showed even more reduction in the size of the knot, and pain was reduced even further. After 32 weeks an MRI scan showed near complete healing of the treated Achilles tendon.

The case report has been published by the scientific journal, CELLR4, the Official Journal of The Cure Alliance. The report can be seen on the CELLR4 website at http://www.cellr4.org/article/1100.

According to Luke Whalen, Biologic Therapies’ CEO, “This is an extremely important development for Biologic Therapies. The case report shows that stem cell therapy is an effective treatment for chronic Achilles tendon injury, which has not been documented before. The report also shows that stem cell therapy for this type of injury can be administered in a physician’s office as a point-of-care outpatient procedure using Biologic Therapies products. There is no need for hospitalization and surgery as would have been the case previously.

“Another important aspect of the publication of this case report is that the scientific journal it was published by is one of the most prestigious publications in the regenerative medicine industry. The members of the CELLR4 Journal Editorial Board that reviewed and approved the report are literally the ‘who’s who’ of regenerative medicine professionals from around the world. We are honored that they chose to publish the report. This helps to reinforce Biologic Therapies’ position as a global leader in regenerative medicine,” said Whalen.

The CELLR4 Editorial Board is led by Editor in Chief, Camillo Ricordi
from the Cell Transplant Center and Diabetes Research Institute at the University of Miami, Miami, Florida, USA. Other editorial staff of note include the Associate Editor for Asia, Jianming Tan
of Fuzhou General Hospital, Xiamen University, China; Assistant Editor, Antonello Pileggi of the Cell Transplant Center and Diabetes Research Institute at the University of Miami, Miami, Florida, USA; and Assistant Board member Arnold I. Caplan
from Case Western Reserve University, Cleveland, Ohio, USA.

In the late 1980’s, Dr. Arnold Caplan and colleagues developed and patented the technology to isolate adult human mesenchymal stem cells (MSCs) from bone marrow and to preserve their multi-potency (Caplan et al., 2001; Koc et al., 1999; Lennon et al., 2006). Adult human MSCs are capable of differentiating into a number of tissue types including bone, cartilage, muscle, marrow, tendon, ligament, adipocytes, and connective tissue.

Over 100 scientists, physicians, researchers and educators from around the world make up the CELLR4 Editorial Board. A complete listing of the Board members can be found at http://www.cellr4.org/editorial-board

About CELLR4
CELLR4 (http://www.cellr4.org) is a scientific journal with particular focus on cellular repair, replacement, regeneration, reprogramming and differentiation. Its scope ranges from fundamental new discoveries in basic science to translational, clinical trials and delivery of novel therapeutic options. As the official journal of the international non-profit organization The Cure Alliance, CELLR4 serves as a platform for discussion of challenges and opportunities on the path to the development of new treatments, independently from the disease target. CELLR4 publishes commentaries and opinion papers on regulatory, legal, and ethical issues, as well as information on global collaborative platforms and funding opportunities of interest to the field.

CELLR4 also serves as the official journal of the Fondazione Cure Alliance Onlus, another non-profit international organization that include physicians, scientists, patients, patient advocates, business and philanthropy leaders, with the mission to promote collaborative efforts worldwide, while addressing and working to resolve impediments and challenges on the path to develop cures for diseases now afflicting humankind. In this direction, the publication serves as a shared communication platform to discuss challenges and opportunities on the path to develop new treatments.

About Biologic Therapies
Based in Ocala, Florida, Biologic Therapies, Inc. (www.biologictherapies.com), is a company with a principal strategy of seeking out and developing innovative, proprietary and patented technologies to meet the needs of the rapidly emerging science of regenerative medicine, including stem cell therapy. Biologic Therapies provides groundbreaking medical technologies that significantly enhance the body’s natural healing ability, thereby providing patients with improved outcomes and quicker restoration of function. The Company’s products provide access to the biologics / regenerative medicine sector of the healthcare market.

Neil Riordan, PhD Presents at American Academy of Anti-Aging Medicine’s 22nd Annual World Congress on Anti-Aging, Regenerative and Aesthetic Medicine in Orlando, May 15

Neil Riordan, PhD will Present “Umbilical Cord Mesenchymal Stem Cells in the Treatment of Autoimmune Diseases” at the 22nd Annual World Congress on Anti-Aging, Regenerative and Aesthetic Medicine at the Gaylord Palms Hotel in Orlando, Florida as part of the Specialty Workshop: “Stem Cells in Anti-Aging Medicine: An Update”.

Orlando, FL (PRWEB) May 13, 2014

Neil Riordan, PhD will Present “Umbilical Cord Mesenchymal Stem Cells (MSC) in the Treatment of Autoimmune Diseases” at the 22nd Annual World Congress on Anti-Aging, Regenerative and Aesthetic Medicine at the Gaylord Palms Hotel in Orlando, Florida as part of the Specialty Workshop: “Stem Cells in Anti-Aging Medicine: An Update”.

The primary focus of this workshop is to teach medical professionals how to successfully incorporate stem cell treatments into their practices. Expert faculty will cover stem cell theory and clinical trial research for all aspects of regenerative medicine as well as stem cell treatment marketing.

Dr. Riordan will discuss: Allogeneic mesenchymal stem cells’ mechanisms of immune modulating activities; the importance of MSC placement for clinical effect; human clinical trials demonstrating efficacy; alternative routes of MSC delivery; dose and frequency; and clinical safety of MSC.

The conference will be held from May 15 – 17, 2014 at the Gaylord Palms Hotel in Orlando, Florida. For more information, please visit http://www.a4m.com/anti-aging-conference-orlando-2014-may.html.

About Neil Riordan PhD
Dr. Riordan is the founder and chairman of Medistem Panama, Inc., (MPI) a leading stem cell laboratory and research facility located in the Technology Park at the prestigious City of Knowledge in Panama City, Panama. Founded in 2007, MPI stands at the forefront of applied research on adult stem cells for several chronic diseases. MPI’s stem cell laboratory is ISO 9001 certified and fully licensed by the Panamanian Ministry of Health. Dr. Riordan is the founder of Stem Cell Institute (SCI) in Panama City, Panama (est. 2007).

Under the umbrella of MPI subsidiary Translational Biosciences, MPI and SCI are currently conducting five IRB-approved clinical trials in Panama for multiple sclerosis, rheumatoid arthritis and osteoarthritis using human umbilical cord-derived mesenchymal stem cells, mesenchymal trophic factors and stromal vascular fraction. Additional trials for spinal cord injury, autism and cerebral palsy are slated to commence in 2014 upon IRB approval.

Dr. Riordan is an accomplished inventor listed on more than 25 patent families, including 11 issued patents. He is credited with a number of novel discoveries in the field of cancer research since the mid-1990s when he collaborated with his father Dr. Hugh Riordan on the effects of high-dose intravenous vitamin C on cancer cells and the tumor microenvironment. This pioneering study on vitamin C’s preferential toxicity to cancer cells notably led to a 1997 patent grant for the treatment of cancer with vitamin C. In 2010, Dr. Riordan received another patent for a new cellular cancer vaccine.

Dr. Riordan is also the founder of Aidan Products, which provides health care professionals with quality nutraceuticals including Stem-Kine, the only nutritional supplement that is clinically proven to increase the amount of circulating stem cells in the body for an extended period of time. Stem-Kine is currently sold in 35 countries.

Dr. Riordan earned his Bachelor of Science at Wichita State University and graduated magna cum laude. He received his Master’s degree at the University of Nebraska Medical Center. Dr. Riordan completed his education by earning a Ph.D. in Health Sciences at Medical University of the Americas.

About Stem Cell Institute Panama
Founded in 2007 on the principles of providing unbiased, scientifically sound treatment options; the Stem Cell Institute (SCI) has matured into the world’s leading adult stem cell therapy and research center. In close collaboration with universities and physicians world-wide, our comprehensive stem cell treatment protocols employ well-targeted combinations of autologous bone marrow stem cells, autologous adipose stem cells, and donor human umbilical cord stem cells to treat: multiple sclerosis, spinal cord injury, osteoarthritis, rheumatoid arthritis, heart disease, and autoimmune diseases.

In partnership with Translational Biosciences, a subsidiary of Medistem Panama, SCI provides clinical services for ongoing clinical trials that are assessing safety and signs of efficacy for osteoarthritis, rheumatoid arthritis, and multiple sclerosis using allogeneic umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC), autologous stromal vascular fraction (SVF) and hU-MSC-derived mesenchymal trophic factors (MTF). In 2014, Translation Biosciences expects to expand its clinical trial portfolio to include spinal cord injury, heart disease, autism and cerebral palsy.

For more information on stem cell therapy:

Stem Cell Institute Website: http://www.cellmedicine.com

Stem Cell Institute
Via Israel & Calle 66
Plaza Pacific Office #2A
Panama City, Panama

About Medistem Panama Inc.

Since opening its doors in 2007, Medistem Panama Inc. has developed adult stem cell-based products from human umbilical cord tissue and blood, adipose (fat) tissue and bone marrow. Medistem operates an 8000 sq. ft. ISO 9001-certified laboratory in the prestigious City of Knowledge. The laboratory is fully licensed by the Panamanian Ministry of Health and features 3 class 10000 clean rooms, class 100 laminar flow hoods, and class 100 incubators.

Medistem Panama Inc.
Ciudad del Saber, Edif. 221 / Clayton
Panama, Rep. of Panama

Phone: +507 306-2601
Fax: +507 306-2601

Web site: http://www.medistempanama.com

About Translational Biosciences
A subsidiary of Medistem Panama Inc., Translational Biosciences was founded solely to conduct clinical trials using adult stem cells and adult stem cell-derived products.

Translational Biosciences Web Site: http://www.translationalbiosciences.com